br Hamza S Bouvier AM Rollot F Lepage C
 Hamza S, Bouvier AM, Rollot F, Lepage C, Faivre J, Bedenne L. Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. Ann Surg Oncol 2014 Aug;21(8):2636–41.
 Hung A, Mullins CD. Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. Oncologist 2013;18(1):54–63.
 Zhao H, Zhang N, Ho V, Ding M, He W, Niu J, et al. Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 2017 Nov 15;124(4):679–87.  Antonio M, Saldana J, Carmona-Bayonas A, Navarro V, Tebe C, Nadal M, et al. Geriat-ric assessment predicts survival and competing mortality in elderly patients with early colorectal Cancer: can it help in adjuvant therapy decision-making? Oncolo-gist 2017 Aug;22(8):934–43.  Mariano C, Williams G, Deal A, Alston S, Bryant AL, Jolly T, et al. Geriatric assessment of older adults with Cancer during unplanned hospitalizations: an opportunity in disguise. Oncologist 2015 Jul;20(7):767–72.  Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Wolff AC, et al. Quality of care for comorbid conditions during the transition to survivorship: differences be-tween cancer survivors and noncancer controls. J Clin Oncol 2013 Mar 20;31(9): 1140–8.
 Loree JM, Cheung WY. Optimizing adjuvant therapy and survivorship care of stage III colon cancer. Future Oncol 2016 Sep;12(17):2021–35.  Hu CY, Delclos GL, Chan W, Du XL. Assessing the 146724-94-9 and completion of adju-vant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol 2011 Dec;28(4):1062–74.  O'Grady MA, Slater E, Sigurdson ER, Meropol NJ, Weinstein A, Lusch CJ, et al. Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative. Clin Colorectal Cancer 2011 Jun;10(2).  Andre, T, Bonnetain, F. Mineur L, Bennouna, J, Desrame, J, Faroux, R et al. Three ver-sus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. J Clin Oncol; 35(15): [Suppl 3500–3500]. The Breast 45 (2019) 48e55
Contents lists available at ScienceDirect
Causes of sick leave, disability pension, and death following a breast cancer diagnosis in women of working age
Anna Plym a, *, Anna L.V. Johansson a, b, Hannah Bower a, Margaretha Voss c, Lars Holmberg d, e, Irma Fredriksson f, g, Mats Lambe a, h
a Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
b Cancer Registry of Norway, Oslo, Norway
c Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
d Translational Urology and Oncology Research, Division of Cancer Studies, King's College London, London, UK
e Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
f Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
g Department of Breast and Endocrine Surgery, Karolinska University Hospital, Stockholm, Sweden
h Regional Cancer Center, Uppsala University Hospital, Uppsala, Sweden
Received in revised form
Cause of death
Objectives: Women diagnosed with breast cancer during working age are transition reaction at increased risk of permanent absence from work, but the underlying medical causes have rarely been studied. We examined the risk of cause-specific sick leave, disability pension, and the competing event death after a breast cancer diag-nosis in a population-based cohort study.
Materials and methods: From the Breast Cancer Data Base Sweden, we identified 16,603 women diag-nosed with stage I-III breast cancer between 2000 and 2012, and 63,773 control women. Using multi-state modelling, we calculated probabilities and durations of sick leave, disability pension, and death by registered cause, together with cause-specific hazard ratios.
Results: Five years after diagnosis, causes other than cancer accounted for around half of all sick leave (3.5% out of 6.8% of women) and disability pension (1.4% out of 2.6%) in women with breast cancer. Compared with control women, women with breast cancer were at increased risk of sick leave and disability pension due to mental disorders (HR 1.24, 95% CI 1.15e1.33 and HR 1.54, 95% CI 1.29e1.85, respectively) and disability pension due to inflammatory diseases (HR 1.46, 95% CI 1.05e2.03). The risk of sick leave and disability pension due to cardiovascular disease was also elevated, although only statis-tically significant for disability pension in women diagnosed after 2005 (HR 2.24, 95% CI 1.22e4.13).